Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Re-arms DSaRM: Recruits Eight Veterans from Safety/Surveillance World

This article was originally published in RPM Report

Executive Summary

The new group of Drug Safety & Risk Management Advisory Committee members comprises a lot of familiar faces. FDA has made use of its extensive outside academic connections, research grants and post-graduate training programs to bring in eight members for the Classes of 2013 and 2014. Most of them have been getting extensive on-the-job training with the advisory committee already.
Advertisement

Related Content

The New Drug Safety Committee Members
Bristol-Myers Squibb/AstraZeneca Onglyza is Guinea Pig for FDA Mini-Sentinel Post-Market Surveillance
Avandia: How do you hold a moon beam in your hand?
FDA Has Key New Constituency for REMS: Advisory Committee Members
Drug Safety in Post-FDAAA Era: An Epidemiologist's View
Avandia's Black Box: FDA's Office of New Drugs Wins
Drug Safety Reform: Did FDA Buy Time or Trouble?

Topics

Advertisement
UsernamePublicRestriction

Register

PS080807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel